Rb/E2F: A two-edged sword in the melanocytic system

[1]  A. Knudson.  Hereditary cancer: Two hits revisited , 2005, Journal of Cancer Research and Clinical Oncology.

[2]  R. Young,et al.  A common set of gene regulatory networks links metabolism and growth inhibition. , 2004, Molecular cell.

[3]  A. Blais,et al.  Hitting their targets: an emerging picture of E2F and cell cycle control. , 2004, Current opinion in genetics & development.

[4]  C. Marshall,et al.  B-RAF is a therapeutic target in melanoma , 2004, Oncogene.

[5]  S. Ariyan,et al.  Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas , 2004, Cancer Research.

[6]  E. Eisenhauer,et al.  Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma , 2004, Investigational New Drugs.

[7]  M. Poetsch,et al.  Loss of heterozygosity at 12p13 and loss of p27KIP1 protein expression contribute to melanoma progression , 2004, Virchows Archiv.

[8]  R. Fotedar,et al.  Rb Inhibits E2F-1-induced Cell Death in a LXCXE-dependent Manner by Active Repression* , 2004, Journal of Biological Chemistry.

[9]  A. Gartel,et al.  Constitutive expression of E2F-1 leads to p21-dependent cell cycle arrest in S phase of the cell cycle , 2004, Oncogene.

[10]  A. Chompret,et al.  Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. , 2004, Journal of the National Cancer Institute.

[11]  D. Morton,et al.  Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients , 2004, Oncogene.

[12]  N. Dyson,et al.  Molecular mechanisms of E2F-dependent activation and pRB-mediated repression , 2004, Journal of Cell Science.

[13]  N. Hynes,et al.  Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins , 2004, Oncogene.

[14]  W. Kaelin,et al.  Gleevec: Prototype or Outlier? , 2004, Science's STKE.

[15]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[16]  B. Spike,et al.  New roles for the RB tumor suppressor protein. , 2004, Current opinion in genetics & development.

[17]  M. Ittmann,et al.  Inhibition of proliferation and survival of melanoma cells by adenoviral-mediated expression of dominant negative fibroblast growth factor receptor , 2004, Melanoma research.

[18]  A. Murray,et al.  Recycling the Cell Cycle Cyclins Revisited , 2004, Cell.

[19]  C. Sherr,et al.  Principles of Tumor Suppression , 2004, Cell.

[20]  M. Hendrix,et al.  Molecular Role(s) for Integrins in Human Melanoma Invasion , 2004, Cancer and Metastasis Reviews.

[21]  R. Halaban.  Melanoma Cell Autonomous Growth: The Rb/E2F Pathway , 2004, Cancer and Metastasis Reviews.

[22]  C. Steer,et al.  The role of retinoblastoma protein in apoptosis , 2004, Apoptosis.

[23]  R. Weinberg,et al.  When cells get stressed: an integrative view of cellular senescence. , 2004, The Journal of clinical investigation.

[24]  M. Gleave,et al.  Regulation of tumor angiogenesis by integrin-linked kinase (ILK). , 2004, Cancer cell.

[25]  W. Hait,et al.  Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  K. Eisenmann,et al.  Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. , 2003, Cancer research.

[27]  M. Vooijs,et al.  Distinct and nonoverlapping roles for pRB and cyclin D:cyclin-dependent kinases 4/6 activity in melanocyte survival , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Cobb,et al.  MAP Kinase Modules: Many Roads Home , 2003, Current Biology.

[29]  F. Mascarelli,et al.  Mutation of B-Raf in Human Choroidal Melanoma Cells Mediates Cell Proliferation and Transformation through the MEK/ERK Pathway* , 2003, Journal of Biological Chemistry.

[30]  L. Cantley,et al.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise. , 2003, Cancer cell.

[31]  D. Huntsman,et al.  Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  F. Dick,et al.  pRB contains an E2F1-specific binding domain that allows E2F1-induced apoptosis to be regulated separately from other E2F activities. , 2003, Molecular cell.

[33]  D. Tuveson,et al.  Suppression of BRAF(V599E) in human melanoma abrogates transformation. , 2003, Cancer research.

[34]  M. Korbonits,et al.  Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours. , 2003, The Journal of endocrinology.

[35]  Meenhard Herlyn,et al.  BRAF as a potential therapeutic target in melanoma and other malignancies. , 2003, Cancer cell.

[36]  L. Chin.  The genetics of malignant melanoma: lessons from mouse and man , 2003, Nature Reviews Cancer.

[37]  S. Lowe,et al.  Rb-Mediated Heterochromatin Formation and Silencing of E2F Target Genes during Cellular Senescence , 2003, Cell.

[38]  C. Pritchard,et al.  Raf proteins and cancer: B-Raf is identified as a mutational target. , 2003, Biochimica et biophysica acta.

[39]  J. McCubrey,et al.  BAY-43-9006 Bayer/Onyx. , 2003, Current opinion in investigational drugs.

[40]  M. Tucker,et al.  Melanoma etiology: where are we? , 2003, Oncogene.

[41]  L. Chin,et al.  The INK4a/ARF locus and melanoma , 2003, Oncogene.

[42]  Carl W. Miller,et al.  Absence of R24C Mutation of the CDK4 Gene in Leukemias and Solid Tumors , 2003, International journal of hematology.

[43]  H. Cam,et al.  Emerging roles for E2F: beyond the G1/S transition and DNA replication. , 2003, Cancer cell.

[44]  Ying Huang,et al.  An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. , 2003, Cancer research.

[45]  R. Halaban,et al.  The tyrphostin AG1024 accelerates the degradation of phosphorylated forms of retinoblastoma protein (pRb) and restores pRb tumor suppressive function in melanoma cells. , 2003, Cancer research.

[46]  Susan M. Kilroy,et al.  Malignant Transformation of Melanocytes to Melanoma by Constitutive Activation of Mitogen-activated Protein Kinase Kinase (MAPKK) Signaling* , 2003, The Journal of Biological Chemistry.

[47]  Pearlly S Yan,et al.  Identification of novel pRb binding sites using CpG microarrays suggests that E2F recruits pRb to specific genomic sites during S phase , 2003, Oncogene.

[48]  W. Kaelin.  E2F1 as a target: promoter-driven suicide and small molecule modulators. , 2003, Cancer biology & therapy.

[49]  E. Nicolas,et al.  Balance between Acetylation and Methylation of Histone H3 Lysine 9 on the E2F-Responsive Dihydrofolate Reductase Promoter , 2003, Molecular and Cellular Biology.

[50]  M. Burghammer,et al.  Crystal structure of the retinoblastoma tumor suppressor protein bound to E2F and the molecular basis of its regulation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Ken Yamamoto,et al.  Self-interaction of heterochromatin protein 1 is required for direct binding to histone methyltransferase, SUV39H1. , 2003, Biochemical and biophysical research communications.

[52]  Tony Kouzarides,et al.  The Methyl-CpG-binding Protein MeCP2 Links DNA Methylation to Histone Methylation* , 2003, The Journal of Biological Chemistry.

[53]  Jean Y. J. Wang,et al.  Coordinated regulation of life and death by RB , 2003, Nature Reviews Cancer.

[54]  L. Chin,et al.  Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[55]  M. Barbacid,et al.  Driving the cell cycle to cancer. , 2003, Advances in experimental medicine and biology.

[56]  Jeong Ho Chang,et al.  Structural basis for the recognition of the E2F transactivation domain by the retinoblastoma tumor suppressor. , 2002, Genes & development.

[57]  E. Harlow,et al.  The retinoblastoma tumour suppressor in development and cancer , 2002, Nature Reviews Cancer.

[58]  Rachel Jones,et al.  Behavioural genetics: Worms gang up on bacteria , 2002, Nature Reviews Neuroscience.

[59]  Ramana V. Davuluri,et al.  Direct coupling of the cell cycle and cell death machinery by E2F , 2002, Nature Cell Biology.

[60]  P. Claudio,et al.  Interview with the retinoblastoma family members: Do they help each other? , 2002, Journal of cellular physiology.

[61]  D. Bennett,et al.  Molecular regulation of melanocyte senescence. , 2002, Pigment cell research.

[62]  Arkady B. Khodursky,et al.  Global analysis of mRNA decay and abundance in Escherichia coli at single-gene resolution using two-color fluorescent DNA microarrays , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[63]  J. Schneider,et al.  Expression of p16, p27, p53, p73 and Nup88 proteins in matched primary and metastatic melanoma cells. , 2002, International journal of oncology.

[64]  K. Tsukuda,et al.  An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. , 2002, Cancer research.

[65]  Stuart L. Schreiber,et al.  Methylation of histone H3 Lys 4 in coding regions of active genes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[66]  T. Jenuwein,et al.  The many faces of histone lysine methylation. , 2002, Current opinion in cell biology.

[67]  J. Dalgaard,et al.  A mark in the core: silence no more! , 2002, Molecular cell.

[68]  D. Pinkel,et al.  Cyclin D1 is a candidate oncogene in cutaneous melanoma. , 2002, Cancer research.

[69]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[70]  F. McCormick,et al.  Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. , 2002, Cancer cell.

[71]  L. Chin,et al.  p16(Ink4a) in melanocyte senescence and differentiation. , 2002, Journal of the National Cancer Institute.

[72]  K. McMasters,et al.  Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors. , 2002, Cancer research.

[73]  M. Barbacid,et al.  Cyclin D-dependent kinases, INK4 inhibitors and cancer. , 2002, Biochimica et biophysica acta.

[74]  S. Pradhan,et al.  The retinoblastoma gene product interacts with maintenance human DNA (cytosine‐5) methyltransferase and modulates its activity , 2002, The EMBO journal.

[75]  S. Rane,et al.  Germ Line Transmission of the Cdk4R24C Mutation Facilitates Tumorigenesis and Escape from Cellular Senescence , 2002, Molecular and Cellular Biology.

[76]  E. Nicolas,et al.  Functional and physical interaction between the histone methyl transferase Suv39H1 and histone deacetylases. , 2002, Nucleic acids research.

[77]  Jeffrey M. Trimarchi,et al.  Transcription: Sibling rivalry in the E2F family , 2002, Nature Reviews Molecular Cell Biology.

[78]  A. Bird.  DNA methylation patterns and epigenetic memory. , 2002, Genes & development.

[79]  C. Allis,et al.  Methylation of Histone H3 at Lys-9 Is an Early Mark on the X Chromosome during X Inactivation , 2001, Cell.

[80]  Pierre Dubus,et al.  Wide spectrum of tumors in knock‐in mice carrying a Cdk4 protein insensitive to INK4 inhibitors , 2001, The EMBO journal.

[81]  T. Mak,et al.  Inactivation of the retinoblastoma tumor suppressor induces apoptosis protease-activating factor-1 dependent and independent apoptotic pathways during embryogenesis. , 2001, Cancer research.

[82]  M. Barbacid,et al.  To cycle or not to cycle: a critical decision in cancer , 2001, Nature reviews. Cancer.

[83]  G. Mann,et al.  Mutations in the INK4a/ARF Melanoma Susceptibility Locus Functionally Impair p14ARF * , 2001, The Journal of Biological Chemistry.

[84]  M.-H. Lee,et al.  Contributions in the domain of cancer research: Review¶Negative regulators of cyclin-dependent kinases and their roles in cancers , 2001, Cellular and Molecular Life Sciences CMLS.

[85]  M. Barbacid,et al.  Invasive melanoma in Cdk4-targeted mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[86]  E. Nicolas,et al.  Transcriptional Repression by the Retinoblastoma Protein through the Recruitment of a Histone Methyltransferase , 2001, Molecular and Cellular Biology.

[87]  P. Duray,et al.  Neonatal sunburn and melanoma in mice , 2001, Nature.

[88]  A. Berns,et al.  Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice , 2001, Nature.

[89]  D. Carrasco,et al.  Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis , 2001, Nature.

[90]  Andrew J. Bannister,et al.  Rb targets histone H3 methylation and HP1 to promoters , 2001, Nature.

[91]  N. Hayward,et al.  No evidence of a role for activating CDK2 mutations in melanoma , 2001, Melanoma research.

[92]  P. K. Davis,et al.  Vivo Cyclin-dependent Kinase Complexes in 1 Tumor Suppressor Protein by G Differential Regulation of Retinoblastoma , 2001 .

[93]  N. Gruis,et al.  Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma. , 2001, Cancer research.

[94]  E. Villa-Moruzzi,et al.  Site-specific and temporally-regulated retinoblastoma protein dephosphorylation by protein phosphatase type 1 , 2001, Oncogene.

[95]  L. Chin,et al.  Genetic dissection of melanoma pathways in the mouse. , 2001, Seminars in cancer biology.

[96]  A. Harel-Bellan,et al.  The Rb/chromatin connection and epigenetic control: opinion , 2001, Oncogene.

[97]  C. Leung-Hagesteijn,et al.  Modulation of integrin signal transduction by ILKAP, a protein phosphatase 2C associating with the integrin‐linked kinase, ILK1 , 2001, The EMBO journal.

[98]  C. Plass,et al.  Methylation matters , 2001, Journal of medical genetics.

[99]  J. Nevins,et al.  The Rb/E2F pathway and cancer. , 2001, Human molecular genetics.

[100]  M. Cobb,et al.  Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. , 2001, Endocrine reviews.

[101]  P. Adams.  Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks. , 2001, Biochimica et biophysica acta.

[102]  L. Chin,et al.  Dual Inactivation of RB and p53 Pathways in RAS-Induced Melanomas , 2001, Molecular and Cellular Biology.

[103]  D. Schadendorf,et al.  Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions* , 2001, Journal of clinical pathology.

[104]  N. Dyson,et al.  Retinoblastoma protein partners. , 2001, Advances in cancer research.

[105]  J. Bartek,et al.  Aberrant p27Kip1 promoter methylation in malignant melanoma , 2000, Oncogene.

[106]  David I. Smith,et al.  Role for the p53 homologue p73 in E2F-1-induced apoptosis , 2000, Nature.

[107]  D. Dean,et al.  Role of the LXCXE Binding Site in Rb Function , 2000, Molecular and Cellular Biology.

[108]  Peter L. Jones,et al.  DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters , 2000, Nature Genetics.

[109]  Duanduan Ma,et al.  Exit from G1 and S Phase of the Cell Cycle Is Regulated by Repressor Complexes Containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF , 2000, Cell.

[110]  R. Halaban,et al.  Deregulated E2f Transcriptional Activity in Autonomously Growing Melanoma Cells , 2000, The Journal of experimental medicine.

[111]  J. D. Weber,et al.  The ARF/p53 pathway. , 2000, Current opinion in genetics & development.

[112]  E. Rubin,et al.  Role of pRB dephosphorylation in cell cycle regulation. , 2000, Frontiers in bioscience : a journal and virtual library.

[113]  T. Jacks,et al.  The retinoblastoma gene family in differentiation and development , 1999, Oncogene.

[114]  E. Medrano,et al.  High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas. , 1999, The Journal of investigative dermatology.

[115]  T. Liu,et al.  Adenovirus‐mediated E2F‐1 gene transfer efficiently induces apoptosis in melanoma cells , 1999, Cancer.

[116]  W. Kaelin,et al.  Functions of the retinoblastoma protein. , 1999, BioEssays : news and reviews in molecular, cellular and developmental biology.

[117]  M. Tucker,et al.  Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  L. Meijer,et al.  ATP-site directed inhibitors of cyclin-dependent kinases. , 1999, Current medicinal chemistry.

[119]  I. Schieren,et al.  Paradoxical increase in retinoblastoma protein in colorectal carcinomas may protect cells from apoptosis. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[120]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[121]  B. Gallie,et al.  Cumulative Effect of Phosphorylation of pRB on Regulation of E2F Activity , 1999, Molecular and Cellular Biology.

[122]  D. Elder,et al.  Progression-related expression of beta3 integrin in melanomas and nevi. , 1999, Human pathology.

[123]  V. Tron,et al.  Expression of cell cycle regulators in human cutaneous malignant melanoma. , 1999, Melanoma research.

[124]  James M. Roberts,et al.  The p21Cip1 and p27Kip1 CDK ‘inhibitors’ are essential activators of cyclin D‐dependent kinases in murine fibroblasts , 1999, The EMBO journal.

[125]  Wei Liu,et al.  Linkage between melanocytic tumor development and early burst of Ret protein expression for tolerance induction in metallothionein-I/ret transgenic mouse lines , 1999, Oncogene.

[126]  M. Hajdúch,et al.  Synthetic Cyclin Dependent Kinase Inhibitors , 1999 .

[127]  M. Hajduch,et al.  Synthetic cyclin dependent kinase inhibitors. New generation of potent anti-cancer drugs. , 1999, Advances in experimental medicine and biology.

[128]  X. Graña,et al.  Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth , 1998, Oncogene.

[129]  Philip D. Jeffrey,et al.  Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a , 1998, Nature.

[130]  K. Tsai,et al.  Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. , 1998, Molecular cell.

[131]  N. Dyson,et al.  Key roles for E2F1 in signaling p53-dependent apoptosis and in cell division within developing tumors. , 1998, Molecular cell.

[132]  J. Nevins,et al.  Toward an understanding of the functional complexity of the E2F and retinoblastoma families. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[133]  J. Nesland,et al.  Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. , 1998, The American journal of pathology.

[134]  Colin A. Johnson,et al.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex , 1998, Nature.

[135]  R. Halaban,et al.  Release of cell cycle constraints in mouse melanocytes by overexpressed mutant E2F1E132, but not by deletion of p16INK4A or p21WAF1/CIP1 , 1998, Oncogene.

[136]  D. Johnson,et al.  Role of E2F in cell cycle control and cancer. , 1998, Frontiers in bioscience : a journal and virtual library.

[137]  Antonio Iavarone,et al.  Regulation of the cdk inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F , 1998, Oncogene.

[138]  R. Halaban,et al.  Release of melanocytes from external growth inhibitory signals by overexpressed mutant transcription factor E2F1E132, but not by disruption of p16INK4A, p21WAF1/CIP1 or p27KIP1 genes , 1998 .

[139]  D. Pinkel,et al.  Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. , 1998, Cancer research.

[140]  Jie-Oh Lee,et al.  Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7 , 1998, Nature.

[141]  D. Dean,et al.  Rb Interacts with Histone Deacetylase to Repress Transcription , 1998, Cell.

[142]  Tony Kouzarides,et al.  Retinoblastoma protein recruits histone deacetylase to repress transcription , 1998, Nature.

[143]  L. Magnaghi-Jaulin,et al.  Retinoblastoma protein represses transcription by recruiting a histone deacetylase , 1998, Nature.

[144]  S. Mittnacht,et al.  Control of pRB phosphorylation. , 1998, Current opinion in genetics & development.

[145]  R. Halaban,et al.  Melanomas, from the cell cycle point of view (Review). , 1998, International journal of molecular medicine.

[146]  Robert A. Weinberg,et al.  Functional Inactivation of the Retinoblastoma Protein Requires Sequential Modification by at Least Two Distinct Cyclin-cdk Complexes , 1998, Molecular and Cellular Biology.

[147]  A. Kamb.  Cyclin-dependent kinase inhibitors and human cancer. , 1998, Current topics in microbiology and immunology.

[148]  P. Pollock,et al.  Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds , 1997, Oncogene.

[149]  N. Hayward,et al.  Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. , 1997, Cancer research.

[150]  J. Massagué,et al.  Differential Interaction of the Cyclin-dependent Kinase (Cdk) Inhibitor p27Kip1 with Cyclin A-Cdk2 and Cyclin D2-Cdk4* , 1997, The Journal of Biological Chemistry.

[151]  P. Wen,et al.  Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector , 1997, Nature Medicine.

[152]  D. Becker,et al.  Antisense targeting of basic fibroblast growth factor and dibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth , 1997, Nature Medicine.

[153]  R. Halaban,et al.  Suppression of autocrine cell proliferation and tumorigenesis of human melanoma cells and fibroblast growth factor transformed fibroblasts by a kinase-deficient FGF receptor 1: evidence for the involvement of Src-family kinases , 1997, Oncogene.

[154]  J. Tímár,et al.  The High Affinity αIIbβ3 Integrin Is Involved in Invasion of Human Melanoma Cells , 1997 .

[155]  V. Tron,et al.  Overexpression of the cyclin‐dependent kinase inhibitor p21WAF1/GIP1 in human cutaneous malignant melanoma , 1997, Journal of cutaneous pathology.

[156]  J. LaBaer,et al.  New functional activities for the p21 family of CDK inhibitors. , 1997, Genes & development.

[157]  L. Bouter,et al.  Second primary tumors in patients with retinoblastoma. A review of the literature. , 1997, Ophthalmic genetics.

[158]  M. Gorospe,et al.  p21Waf1/Cip1 protects against p53-mediated apoptosis of human melanoma cells , 1997, Oncogene.

[159]  J. Harper,et al.  Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. , 1997, Molecular biology of the cell.

[160]  J. Tímár,et al.  The high affinity alphaIIb beta3 integrin is involved in invasion of human melanoma cells. , 1997, Cancer research.

[161]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[162]  J. Bartek,et al.  The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. , 1996, Cancer research.

[163]  R. Kerbel,et al.  Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions. , 1996, The American journal of pathology.

[164]  R. Weinberg,et al.  Cell-cycle control and its watchman , 1996, Nature.

[165]  E. Hovig,et al.  Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. , 1996, British Journal of Cancer.

[166]  P. Smith,et al.  A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. , 1996, Oncogene.

[167]  Dracopoli Nc,et al.  CDKN2 mutations in melanoma. , 1996 .

[168]  N. Hayward,et al.  Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma , 1996, Nature Genetics.

[169]  D. Livingston,et al.  Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint , 1995, Cell.

[170]  M. Serrano,et al.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.

[171]  C. Sherr,et al.  D-type cyclins. , 1995, Trends in biochemical sciences.

[172]  J. A. Bishop,et al.  Retinoblastoma, melanoma and the atypical mole syndrome , 1995, The British journal of dermatology.

[173]  C. Peng,et al.  Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation , 1994, Molecular and cellular biology.

[174]  M. Herlyn,et al.  Protein kinases in normal and transformed melanocytes , 1994, Melanoma research.

[175]  R. DePinho,et al.  p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens , 1994, Nature.

[176]  M. Skolnick,et al.  Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus , 1994, Nature Genetics.

[177]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[178]  W. Silvers,et al.  Transgenic mouse model of malignant skin melanoma. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[179]  M. Herlyn,et al.  Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation. , 1992, Oncogene.

[180]  R. Weinberg,et al.  Effects of an Rb mutation in the mouse , 1992, Nature.

[181]  A. Bradley,et al.  Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis , 1992, Nature.

[182]  D. Birnbaum,et al.  DNA amplification at 11q13 in human cancer: from complexity to perplexity. , 1992, Mutation research.

[183]  D. Birnbaum,et al.  Fibroblast Growth Factors in Normal and Malignant Melanocytes a , 1991, Annals of the New York Academy of Sciences.

[184]  R. Weinberg,et al.  Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[185]  R. Halaban,et al.  Transformation of murine melanocytes by basic fibroblast growth factor cDNA and oncogenes and selective suppression of the transformed phenotype in a reconstituted cutaneous environment , 1989, The Journal of cell biology.

[186]  U. Francke,et al.  Cytogenetic analysis of melanocytes from premalignant nevi and melanomas. , 1988, Journal of the National Cancer Institute.

[187]  R. Weinberg,et al.  Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[188]  W. Lee,et al.  Human retinoblastoma susceptibility gene: cloning, identification, and sequence , 1987, Science.

[189]  W. W. Nichols,et al.  Chromosomal deletion and retinoblastoma. , 1976, The New England journal of medicine.

[190]  U. Francke,et al.  Sporadic bilateral retinoblastoma and 13q- chromosomal deletion. , 1976, Medical and pediatric oncology.

[191]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.